Kornimate/medical-research-clean huggingface dataset:
isokinetic strength and balance assessment in diabetic patients

Conditions: Diabetes

Summary: diabetic polyneuropathy (dpn) is a type of nerve damage that can occur in diabetics. it can cause weakness and a loss of sensation, particularly in the legs and feet. this can have an impact on muscle strength and balance, making walking more difficult and increasing the risk of falling. evaluating ankle muscular strength and balance using quantitative and standardised tools is critical for patients with and without dpn as well as determining how much dpn affects ankle muscle strength and balance.

diabetic peripheral neuropathy (dpn) can affect ankle muscle strength and increase the risk of falling. this occurs due to nerve damage that impairs muscle function and reduces sensitivity in the feet, leading to difficulty maintaining balance and coordination. risk factors for dpn-related falls include poor glycemic control, the duration of diabetes, age, and other comorbidities such as peripheral vascular disease. it is important for individuals with diabetes to regularly monitor and manage their dpn to prevent falls and maintain overall health. so, conducting this study to measure ankle muscle strength through isokinetic testing and dynamic balance through the biodex balance system will help researchers quantify the extent of dpn's impact on these aspects. this study can provide a valuable predictor and assessment tool for determining the severity of neuropathy in diabetic patients. the results of this study could also help identify those at a higher risk for falls and diabetic foot complications. this information can aid healthcare providers in developing tailored interventions to improve muscle strength and balance and reduce the risk of falls in individuals with diabetes and dpn.

Eligibility criteria:
inclusion criteria: 1. patients aged from 40 to 55 years for both gender. 2. patients with diabetes for more than 5 years. 3. diabetic polyneuropathy was diagnosed by a neurologist. 4. their bmi from 18 to 24.9 kg/m2. 5. the study population must be willing to participate in the study. exclusion criteria: 1. patients with marked deformities of the lower limbs, foot ulcers and charcot foot. 2. .patients with any other neurological or orthopedic diseases that may affect balance. 3. patients with marked weakness or drop foot. 4. patients with amputation, mental deficits, liver or renal diseases. 5. patients who had a previous surgical history (within 6 months) were also excluded prior to the baseline assessment

Keywords: diabetes, diabetic polyneuropathy isokinetic muscle strength dynamic balance
severing nuchal cord at the time of delivery.

Conditions: Perinatal Outcome

Summary: umbilical cord often becomes encircled around portions of the fetus, usually the neck. the incidence ranges from 1 loop in 21% to 3 loops in 0.2%. in this study we wish to assessed the practice of severing the cord, which was encircled once around the neck of the fetus, after delivery of the anterior shoulder and prior to extraction of the body. the study and the control groups will include 30 women, each one. after diagnosis of cord around the neck during labor by ultrasound, the women will inter a randomization process. after delivery of the head, it will be cut intentionally in the study group and left intact in the control group. neonatal outcome will be assessed.

umbilical cord often becomes encircled around portions of the fetus, usually the neck. the incidence ranges from 1 loop in 21% to 3 loops in 0.2%. in this study we wish to assessed the practice of severing the cord, which was encircled once around the neck of the fetus, after delivery of the anterior shoulder and prior to extraction of the body. the study and the control groups will include 30 women, each one. after diagnosis of cord around the neck during labor by ultrasound, the women will inter a randomization process. after delivery of the head, it will be cut intentionally in the study group and left intact in the control group. neonatal outcome will be assessed.

Eligibility criteria:
inclusion criteria: single loop cord around the neck active labor spontaneous vaginal delivery exclusion criteria: instrumental delivery cesarean section false positive finding of cord around the neck multiple loop cord around the neck
a study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of ap611074 5% gel for up to 16 weeks in condyloma patients

Conditions: Condyloma

Summary: this is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of ap611074 5% gel for up to 16 weeks in condyloma patients


Eligibility criteria:
inclusion criteria: 1. male or female patient aged between 18 and 55 years. 2. external condylomas, 2-30 lesions (no more than 2 lesions side by side); flat or papular, but not pediculated. 3. lesions must not be internal. lesions that originate internally, but are visible externally will be considered internal and are not allowed in the study. 4. total wart area (diameter x diameter) should not be less than 10mm2 and not more than 800 mm2 5. individual wart area should not measure more than 50mm2, and the major perpendicular diameter should not measure more than 10mm (1cm). 6. lesions to be treated should have appeared between 1 to 6 months before screening, and patients should not have received any previous condyloma treatment during the last 2 months before enrollment. 7. for female patients: either postmenopausal, taking adequate contraceptive method or surgically sterile. exclusion criteria: 1. patients should not have received genital wart treatment for previous condylomas (other than the prior treatment for current condylomas referred at inclusion criteria) in the last 12 months before enrollment 2. patients with any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease, transplanted or immunosuppressed patients or other clinical condition that, in the investigator's judgment, prevents the patients from participating to the study. 3. patients with any clinically significant abnormality following review of screening laboratory tests, vital signs, full physical examination and ecg. 4. patients with history or presence of drug or alcohol abuse. 5. patients with positive hbs or hbc antigen or anti hcv antibody, or positive results for hiv 1 or 2 tests. 6. patients using any dermatological drug therapy in the treatment area during the last month prior the first application of the study drug.

Keywords: genital warts hpv types sexually transmitted disease papillomavirus infections viral disease anogenital warts agw hpv6 hpv11 human papillomavirus infection hpv aviragen therapeutics, inc. aviragen therapeutics aviragen
role of the nasal environment in obesity

Conditions: Adiposity

Summary: the primary aim of this study is to investigate the nasal environment in obese and lean individuals.


Eligibility criteria:
inclusion criteria: n=50 adult male and female patients with obesity will be included in this study. inclusion criteria: inclusion criteria: * age 18-55 years * written informed consent * bmi \> 30 kg/m2 n=50 adult lean patients age- and sex-matched to the group of obese patients will be included in this study. inclusion criteria: * age 18-55 years * written informed consent * bmi 18-25 kg/m2 n=50 adult male and female patients with obesity with scheduled bariatric will be included in this study inclusion criteria: * age 18-55 years * written informed consent * bmi \> 35 kg/m2 exclusion criteria: * smoking * chronic or acute sinusitis * surgical intervention of the nasal cavity or the paranasal sinus * use of antibiotics within the last 31 days18 * current illicit drug abuse including daily marijuana or cbd consumption (≤ 24 g of alcohol per day allowed) * any kind of severe chronic disease (e.g. severe heart failure, active cancer disease) * use of any kind of decongestant more than twice a week * use of cortisone-containing nasal spray within the last 3 months * acute allergic rhinitis * history of neurodegenerative diseases * history of severe head trauma * severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2)

Keywords: adiposity olfactory function microbiome
clinical study on extracorporeal shock wave therapy for rotator cuff injuries

Conditions: Rotator Cuff Injuries

Summary: this clinical trial aims to learn about the effect of extracorporeal shock wave therapy on rotator cuff injuries. the main question it aims to answer is the efficacy of extracorporeal shock wave therapy on the improvement of pain, shoulder function, and quality of life in patients with rotator cuff injuries. the experimental group of patients received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. the control group only received conventional rehabilitation therapy. compare the two groups to explore the therapeutic effect of extracorporeal shock wave therapy on rotator cuff injuries.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of rotator cuff injuries in 2019 american academy of orthopaedic surgeons clinical practice guideline for rotator cuff injuries (diagnostic criteria: （1）the clinical signs included positive empty cup test and full cup test, positive internal rotation resistance test in abduction and external rotation position and positive jobe sign in lateral position. (2) imaging: magnetic resonance imaging, magnetic resonance arthrography or ultrasound showed rotator cuff injuries, including supraspinatus, infraspinatus, teres minor and subscapularis tendon injuries); * definite imaging diagnosis: magnetic resonance imaging, magnetic resonance arthrography or ultrasound examination; * the shoulder joint did not receive surgical treatment; * both sexes, aged 20-80 years old; * stable vital signs, good communication, and active cooperation to complete the relevant evaluation and treatment; * informed consent was obtained from patients or their families before treatment. exclusion criteria: * mri showed medium, large and huge full-thickness rotator cuff tears; * skin damage or skin disease at the application site; * previous history of shoulder surgery; * pregnant or lactating women; * allergic constitution; * patients with primary diseases of the heart, liver, kidney, or hematopoietic system, patients with mental disorders, patients with built-in cardiac pacemaker, and patients with implanted metal medical devices; * complicated with other diseases that cause body pain; * unable to cooperate with the completion of the whole treatment and follow-up.

Keywords: rotator cuff injuries extracorporeal shockwave therapy
a trial of different methods for bladder drainage in hip surgery patients

Conditions: Urinary Tract Infections

Summary: the aim of the project is to evaluate differences between intermittent and indwelling catheterisation in patients with hip surgery. specific objectives are to determine whether: * frequencies of urinary tract problems in hospital and up to one year after discharge differ between patient groups treated with intermittent and indwelling catheterisation respectively. * costs and health-effects differ between the patient groups. * experiences of urinary catheterisation differ between the patient groups


Eligibility criteria:
inclusion criteria: * patients undergoing hip fracture surgery or hip replacement due to arthrosis * age 50 years and above exclusion criteria: * patients with an indwelling catheter in situ * cognitive impairment

Keywords: urinary tract infections urinary catheterisation
adibelimab, famitinib and chemotherapy for advanced nsclc after pd-1 inhibitor failure

Conditions: Non Small Cell Lung Cancer

Summary: this prospective, single-arm trial explores the efficacy of adibelimab monoclonal antibody combined with famitinib and chemotherapy in treating locally advanced or metastatic nsclc patients with negative driver genes who have progressed after pd-1 monoclonal antibody and chemotherapy treatment. the study focuses on assessing progression-free survival (pfs) in 40 participants. key objectives include evaluating pfs and understanding the progression patterns post-first-line immunotherapy, with an interest in whether switching from pd-1 to pd-l1 inhibitors can overcome immune resistance.

this study is a prospective, single-arm clinical investigation. it aims to assess the effectiveness of the adibelimab monoclonal antibody in combination with famitinib and chemotherapy for treating patients with locally advanced or metastatic non-small cell lung cancer (nsclc) without driver mutations, who have progressed following initial treatment with pd-1 monoclonal antibodies and chemotherapy. the study's primary focus is on evaluating progression-free survival (pfs) among the 40 participants, spanning from december 2023 to december 2026. it intends to explore the therapeutic potential of switching from pd-1 to pd-l1 inhibitors in overcoming immune resistance and identify subgroups that may particularly benefit from this treatment strategy, thereby providing insights into personalized therapy for advanced nsclc.

Eligibility criteria:
inclusion criteria: * participants must be adults (≥18 years) who have signed an informed consent form. * they should have an ecog performance status of 0-1. diagnosed with stage iiib-iv nsclc and have progressed after pd-1 inhibitor treatment. * expected to live at least 3 months and have at least one measurable lesion per recist v1.1. * laboratory test results must meet specific criteria for blood counts, liver and kidney function, and coagulation parameters. * patients with stable, treated brain metastases are eligible. * women of childbearing potential and men with partners of childbearing potential must agree to use contraception. exclusion criteria: * prior therapy with anti-pd-l1, anti-pd-l2, other immune checkpoint inhibitors, or specific cancer treatments. * certain cancer types, known mutations, or recent use of systemic corticosteroids or immunosuppressive medications. * active brain or leptomeningeal metastases without stability post-treatment, recent severe infections, or major surgery. * other conditions that might interfere with the study, such as uncontrollable third-space fluid accumulations, active autoimmune diseases or infections, significant bleeding or thromboembolic events, serious heart conditions, severe allergies to study drugs, other active malignancies, hiv/aids, hepatitis b or c infection, or participation in another interventional clinical study within a specified period.
development of a mobile application for hbb prompt study

Conditions: Birth Asphyxia; Neonatal Death

Summary: this study applies an iterative user-centred design approach involving frontline birth attendants to create a mobile application ("hbb prompt") to improve skills retention after initial newborn stabilization training through the helping babies breathe (hbb) program. hbb prompt will then be piloted at one site after hbb training and skills retention will be compared with a control site without hbb prompt after hbb training.

helping babies breathe (hbb) is a newborn stabilization course that has been shown to reduce neonatal mortality by up to 47%. such mortality impact is however not sustained due to rapid skills deterioration. the investigators propose to improve sustainability of hbb's impact by increasing skills retention with an innovative mobile application called hbb prompt. hbb prompt will be an interactive tool that guides frontline providers through the steps needed to save newborn babies at birth. hbb prompt will facilitate individual and group training in health facilities using the low dose high frequency model (ldhf) for resuscitation skills retention. the investigators will robustly develop hbb prompt by integrating human factors and user-centered design approaches. the investigators will engage end-users and hbb master trainers to iteratively collect feedback to develop hbb prompt for both individual and small group resuscitation practice. the iterative approach will mitigate the common scenario of mobile health (mhealth) solutions unable to achieve sustained success at scale due to lack of comprehensive input from frontline users. the investigators will pilot the app at a single centre and compare it to a control site for hbb skills retention at different time points after initial hbb training.

Eligibility criteria:
inclusion criteria: * frontline birth attendants involved in the delivery or care of babies in the maternity ward, theater or pediatric wards with a possibility of involvement in newborn resuscitation. exclusion criteria: * health workers providing care in other wards other than maternity and pediatrics.

Keywords: helping babies breathe newborn resuscitation skills retention mobile health user-centred design
predicting nociplastic pain in carpal tunnel syndrome through quantitative sensory testing

Conditions: Carpal Tunnel Syndrome

Summary: this study aims to investigate the predictive value of quantitative sensory testing (qst) in identifying patients with carpal tunnel syndrome (cts) who are at risk of developing nociplastic pain.

the study will recruit 120 adults diagnosed with cts and conduct baseline qst measures. the progression to nociplastic pain will be assessed over a one-year follow-up period to determine the predictive value of qst measures.

Eligibility criteria:
inclusion criteria: * adults ages 18-60 * clinical diagnosis of cts based on presence of parasthesias and/or pain in median nerve distribution, positive phalen's test and/or tinel's sign, and nocturnal symptoms * electrodiagnostic evidence of median neuropathy at the wrist: 1. prolonged median motor distal latency \>4.2 ms 2. prolonged median sensory latency \>3.4 ms * symptom duration between 6 months and 2 years (to exclude very early or very late stages) * pain severity of ≥5 on 0-10 numerical rating scale * no evidence of thenar muscle atrophy on physical exam * no prior surgery or fracture of the affected wrist * no evidence of comorbid diabetes mellitus, cervical radiculopathy, polyneuropathy, or other neuromuscular disorders exclusion criteria: * diabetes mellitus, as a common cause of polyneuropathy, which can confound qst measures. * cervical radiculopathy or other upper limb neuropathies, which can cause overlapping sensory symptoms and signs. * history of wrist fracture or surgery, which may cause structural abnormalities affecting nerve function. * pregnancy, due to physiological changes that can affect nerve function. * patients with severe thenar muscle atrophy, indicating long-standing severe median neuropathy. * patients unable to provide informed consent or comply with study procedures.
hippocampus avoidance during intensity modulated radiotherapy for t4 nasopharyngeal carcinoma patients

Conditions: Nasopharyngeal Carcinoma

Summary: this is a prospective, non-randomized phase iii study observing the cognitive function changes with conformal hippocampus avoidance during intensity modulated radiotherapy for t4 nasopharyngeal carcinoma patients.

all patients received intensity modulated radiotherapy or tomotherapy with or without chemotherapy. before radiotherapy, the patients will receive brain mri scanning and the brain mri images will be fused with the head and neck ct scan images. the investigators develop the treatment plan with hippocampus avoidance. cognitive function are evaluated before,during and after radiotherapy. dose-volume histograms are got to analyze the associated factors.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologic confirmed nasopharyngeal carcinoma 2. ecog performance scale 0-2 3. tumor stage is t4n0-3m0-1 according to 8th american joint commission on cancer edition 4. adequate hepatic, renal and hematologic functions (hemoglobin ≥ 90g/l, platelets ≥ 100×10\^9/l, neutrophils ≥ 1.5×10\^9/l, serum transaminase \ 60ml/min. 5. informed consent signed. exclusion criteria: 1. history of malignant tumors. 2. any severe complications contraindicated chemotherapy or radiotherapy. 3. medical history of central nervous system, cognitive or psychological diseases; 4. pregnant or nursing women. 5. patients with mental disease cannot complete the questionaire. 6. mri contraindication -

Keywords: hippocampus avoidance cognitive changes intensity modulated radiotherapy
paracetamol and patent ductus arteriosus (pda)

Conditions: Patent Ductus Arteriosus

Summary: the investigators propose that paracetamol will be similarly effective to ibuprofen in treating pda in the premature neonate, with fewer side effects.

preterm neonates with a hemodynamically significant pda will potentially be candidates for study. after obtaining parental consent, the infants will be prospectively and randomly assigned to one of two groups: 1.po paracetamol at a dose of 15 mg/kg every 6 hours at x 3 days or group 2- iv indomethacin - 0.2 mg/kg/dose q 12h for three doses; or iv ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).clinical staff will be blinded as to the study group assignment of the babies and since the group 1 drug is to be given every six hours, all babies will receive a parenteral substance every 6 hours. for group 2 infants, the intermittent doses will be iv d5w alternating with drug.all infants will fed trophic feeds (20 cc/kg/day) during the treatment for ductal closure.

Eligibility criteria:
inclusion criteria: * echocardiographic diagnosis of hemodynamically significant patent ductus arteriosus exclusion criteria: * major congenital anomalies * life-threatening infection * active nec and/or intestinal perforation * recent (within the previous 24 hours) intraventricular hemorrhage grade 3-4 * urine output \<1 ml per kilogram per hour during the preceding 8 hours * serum creatinine concentration of \>1.6 mg % * platelet count of \<60,000 per cc.

Keywords: pda paracetamol indomethacin ibuprofen
prediction of secondary neurological deterioration in patients with moderate traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: patients with moderate traumatic brain injury (mtbi) are 1,5 times more frequent than those with severe tbi and some of them will develop secondary neurologic deterioration (snd) within the first 7 days. however, identifying at risk patients of snd is still challenging. this study aimed to determine risk factors associated with snd after mtbi.


Eligibility criteria:
inclusion criteria: * adults * admitted in brest hospital between 2015 and 2018 for moderate tbi, defined by glasgow coma scale (gcs) score 9-13 exclusion criteria: * non consenting patients